Purpose: Neuroblastoma (NB) is a neural crest-derived tumor that commonly occurrs in childhood. β-1,4-galactosyltransferase III (B4GALT3) is highly expressed in human fetal brain and is responsible for the generation of poly-N-acetyllactosamine which plays a critical role in tumor progression. We therefore investigated the expression and role of B4GALT3 in NB.
Translational Relevance
Although the overall prognosis of NB patients has improved with the advancement in recent therapies, the long-term survival of high-risk NB remains only 40% despite of intensive multimodal therapy. Therefore, understanding the NB pathogenesis and identification of novel therapeutic targets are crucial to improve outcomes of NB patients. Here we report that B4GALT3 expression is associated with unfavorable histology and stage as well as low survival rate. B4GALT3 expression is an independent prognostic factor for poor survival of NB patients. In addition, B4GALT3 overexpression increases malignant behaviors of NB cells in vitro and in vivo, whereas B4GALT3 knockdown suppresses the malignant phenotypes. Mechanistic investigation suggests that B4GALT3 enhances the malignant phenotypes via alteration of β1 integrin glycosylation and activation of its signaling pathway. Our results reveal the pathologic and biologic role of B4GALT3 in NB development and suggest that B4GALT3 may serve as a novel therapeutic target for NB treatment.
Introduction
Neuroblastoma (NB), which accounts for 10% of pediatric cancers, is a common solid malignant tumor derived from embryonic neural crest cells of sympathetic nervous system, and most frequently from adrenal medulla (1) (2) (3) . The disease exhibits extreme heterogeneity, from spontaneous regression as in differentiated ganglioneuroma to malignant progression as in undifferentiated neuroblastoma, in relation to the diverse biological features of the tumor (1, 4) . Metastasis, an NB staging factor, is found in 50 to 60% of all NB cases; and advanced NBs typically metastasize to distant lymph nodes, bone marrow, bone, liver, or other organs. Although the overall prognosis of NB patients has remarkably improved with the advancement in recent therapies, the long-term survival of high-risk NB remains only 40% despite of intensive multimodal therapy (1) (2) (3) . Finding new prognostic factors is necessitated to further classify and tailor therapy for improving outcome of patients with unfavorable neuroblastoma.
Glycosylation is the most common post-translational modification of proteins and regulates many cellular and developmental properties, including cell proliferation, differentiation, migration, invasion, and immune responses (5) . Aberrant expression of glycans is observed in most human cancers and is associated with malignant transformation and tumor progression (6) . Poly-N-acetyllactosamines are often further modified to present tumor-associated antigens, such as sialyl Lewis X, Lewis X, polysialic acid, and human natural killer-1 (HNK-1) carbohydrate. These glycans play critical roles in modulating cancer metastasis, intracellular protein trafficking, and neuronal development (7) (8) (9) .
The β-1,4-galactosyltransferase III (B4GALT3) belongs to the β-1,4-galactosyltransferase (B4GALT) family, which consists of 7 members with distinct tissue distributions, acceptor preferences, and biological functions. The
B4GALTs transfer galactose from UDP-Gal to N-acetylglucosamine (GlcNAc)-terminated oligosaccharides on N-glycan, O-glycan, or glycolipid to form
N-acetyllactosamine (LacNAc) (10) . B4GALT3 is widely expressed in human tissues and the fetal brain expresses much higher levels of B4GALT3 than does adult brain (11, 12) . Previous in vitro study showed that B4GALT3 prefers adding galactose to the beginning of a poly-N-acetyllactosamine chain (13) . However, roles of B4GALT3
in NB and its effects on NB tumor cells are still unclear.
Integrins are cell surface receptors of extracellular matrix (ECM) proteins and consist of α-and β-subunits. Eighteen α-subunits and 8 β-subunits assemble into 24 different integrins. Amongst which, 12 contain β1-subunit (14) .
Changes in carbohydrates on
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Author Manuscript Published OnlineFirst on February 26, 2013 ; DOI: 10.1158/1078-0432.CCR- β1 integrin have been reported to regulate integrin activity, resulting in altered cell adhesion and metastasis. Overexpression of N-acetylglucosaminyltransferase III (GnT-III) increases the synthesis of bisecting GlcNAc structures on N-glycans and inhibits α5β1-mediated cell spreading and migration (15) . In contrast, increase in β-1,6-GlcNAc branching on N-glycans by N-acetylglucosaminyltransferase V (GnT-V) enhances cell migration toward fibronectin and cell invasion (16) . B3GNT6 (core3 synthase) adds core 3 O-glycan to α2 and β1 integrin subunits to suppress tumor formation and metastasis in prostate cancer (17) . However, effects of B4GALT3 on the glycosylation and function of β1 integrin have not been reported.
The fetal brain expresses much higher levels of B4GALT3 than does adult brain (11) and the public microarray datasets from Oncogenomics: Oberthuer Lab (http://home.ccr.cancer.gov/oncology/oncogenomics/) reveals that, after p value minimization, only B4GALT3, but not other B4GALTs, predicted poor survival of NB patients. We therefore hypothesize that B4GALT3 could be a prognostic factor contributing to the pathogenesis of NB. In this study, we showed that B4GALT3 expression was upregulated in NB and its expression correlated with advanced stage, unfavorable histology, and predicted a poor prognosis in NB patients. In addition, B4GALT3 expression increased cell migration, invasion, and tumor growth of NB cells. Mechanistic investigation showed that B4GALT3 modified glycosylation of β1 integrin through increasing terminal galactose, and regulated the expression of mature form of β1 integrin and its signal transduction. These findings suggest that B4GALT3 enhances malignant properties of NB cells probably via modifying glycosylation and signaling of β1 integrin. This study is the first to report the pathologic and biologic roles of B4GALT3 in NB and suggests that B4GALT3 may be a potential therapeutic target for NB treatment.
Materials and Methods

Patients and tissue samples
Tissue samples were collected from 101 NB patients receiving treatment at the National Taiwan University Hospital between December 1, 1990, and December 31, 2009 with sufficient tumor tissues and complete follow-up were included in this study.
Tumor tissues were obtained from resection or biopsy of the primary or metastatic tumors prior to any chemotherapy or radiotherapy. The use of human tissues for this study was approved by the National Taiwan University Hospital Ethics Committee and written consent was obtained from patients before collection of sample. Tissue specimens were fixed in 4% (w/v) paraformaldehyde/PBS. The details of tumor staging, histological classification and patient treatment have been described
Research. elsewhere (18) . The demographics of this patient cohort can be found in Table 1 .
Immunohistochemistry
Paraffin-embedded tissue sections were deparaffinized in xylene and rehydrated in a series of graded alcohols. After incubation of 3% H 2 O 2 in PBS with 0.1% Triton X-100 at RT for 10 min, the sections were blocked with 5% BSA in PBS for 30 min.
Sections were incubated with a rabbit polyclonal anti-B4GALT3 antibody (Sigma-Aldrich) at 1:100 in 1% BSA/PBS at 4°C for 16 h and followed by incubation at RT for 1 h. After rinsing twice with PBS, Super Sensitive Link-Label immunohistochemistry Detection System (BioGenex) was applied to tissue sections.
The specific immunostaining was then visualized with 3,3-diaminobenzidine liquid substrate system (Sigma-Aldrich). All sections were counterstained with hematoxylin and mounted with UltraKitt (J.T. Baker). Negative controls were performed by replacing primary antibodies with a control non-immune IgG at the same concentration. The immunoreactivity of B4GALT3 in NB tumors was categorized into 4 groups: "0" (no expression); "1+" (weak expression, expression in ~10% to 35% of neuroblastic cells); "2+" (moderate expression, expression in ~35% to 70% of neuroblastic cells); "3+" (strong expression, expression in > 70% of neuroblastic cells.
Cell culture and transfection
Research. selected with 1 μg/ml puromycin (Millipore) for one week, cells were injected subcutaneously into mice for in vivo cell growth observation.
Plasmid construction
Human full-length B4GALT3 was cloned from SH-SY5Y cells. The sense primer was 5'-GGATCCAGGATGTTGCGGAGGCTGCTGGA-3', and antisense primer was 
MTT assay
Cells were seeded in hexaplicate wells of 96-well plates, and each well contained 2 × 
Tumor growth in vivo
For in vivo tumor growth analysis, 6-week-old female SCID mice and 7-week-old
Research. 
Cell differentiation assay
Cells were seeded on plates for 1 day and serum-starved on the following day. Cells were lysed and cell lysates were collected for analyses of βIII-tubulin expression by Western blotting.
Matrigel invasion assay
Cell The number of invaded cells per field was counted and presented as mean ± SD values from at least three independent experiments. The cell numbers were counted by two investigators.
Transwell migration assay
Transwell migration assays were performed using 8-μm pore, 6. 
Integrin degradation assays
Cells were seeded on 12-well plates and adhered for 24 h. Cycloheximide (10 μg/ml) (Sigma-Aldrich) was added to the cells for the indicated time points. Cells were lysed in lysis buffer (Tris 20 mM, pH 8.0, NaCl 137 mM, 1% NP-40, 10% glycerol, Na 3 VO 4 2 mM, β-glycerophosphate 2 mM, PMSF 2 mM, and 1% protease inhibitor cocktail (Sigma-Aldrich)) and β1 integrin protein levels were determined by Western blotting. β-Actin was used as an internal control. The 0 h-control was set to 100% and the detected level of β1 integrin was calculated as the percentage of 0 h-control for each time point.
Statistical analyses
Data are presented as means ± SD. Statistical analyses are carried out using SPSS 10.0 for Windows software (SPSS Inc., Chicago, IL). Student's t test was used to compare differences between two experimental groups. Pearson's chi-square test was used to assess the association between pairs of categorical variables. Survival probabilities in various subgroups were estimated using Kaplan-Meier method, and the significant differences in each group were analyzed by log-rank tests. Each factor 
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B4GALT3 expression and clinicopathologic and biologic factors of NB tumors
We analyzed the public microarray datasets from Oncogenomics: Oberthuer Lab and found that, after p value minimization, only B4GALT3, but not other B4GALTs, predicted poor survival of NB patients ( Supplementary Fig. S1A ). In addition, data from Oncogenomics: Seeger Lab also showed that B4GALT3 high expression test) ( Table 1 ). The percentage of positive B4GALT3 expression was also significantly higher in high risk group patients than that in intermediate or low risk group patients (P = 0.012, χ2 test) ( Table 1) .
B4GALT3 expression and patient survival
Kaplan-Meier analysis showed that NB patients with positive B4GALT3 expression had a lower predictive 5-year survival rate compared to those with negative B4GALT3 expression (40.0% and 76.2% respectively, Fig 1C; discrimination, the impact of B4GALT3 expression on survival rate was analyzed against COG risk grouping. The result revealed that except in patients of low risk with a very good outcome, positive B4GALT3 staining in NB tumors constantly predicted poorer prognosis for patients with either intermediate risk ( Fig. 1D ; P = 0.045, log-rank test) or high risk disease ( Fig. 1E ; P = 0.015, log-rank test). These results suggest that B4GALT3 expression is an independent prognostic factor of poor survival for NB patients and may provide complimentary prognostic information in addition to COG risk classification.
Expression of B4GALT3 enhances malignant phenotypes of NB cells
To elucidate effects of B4GALT3 on NB cell behaviors, we overexpressed B4GALT3 in SH-SY5Y and SK-N-AS cells (those do not express B4GALT3) or transiently knocked down B4GALT3 in SK-N-DZ and SK-N-BE cells (those express B4GALT3 endogenously). The overexpression or knockdown of B4GALT3 was confirmed by Western blotting and immunofluorescence staining ( Fig. 2A; Supplementary Fig.   S2A ). Our results showed that B4GALT3 expression did not significantly affect cell growth by MTT assays observed for 4 days in all experimental cell lines ( 
starvation-triggered neuronal differentiation (Fig. 2D, left panels) and knockdown of B4GALT3 in SK-N-DZ directly increased neuronal differentiation without serum-starvation (Fig. 2D, right panels) .
To examine effects of B4GALT3 on cell migration and invasion, transwell migration assay and matrigel invasion assay were performed, respectively. Our results showed that B4GALT3 overexpression significantly enhanced migration and invasion in SH-SY5Y ( Fig. 2E and F) and SK-N-AS cells ( Supplementary Fig. S5A and B) .
Conversely, knockdown of B4GALT3 significantly suppressed migration and invasion in SK-N-DZ ( Fig. 2D and E) and SK-N-BE cells ( Supplementary Fig. S5A and B) .
These results suggest that B4GALT3 expression enhances NB cell migration and invasion in vitro and contribute to tumor growth in vivo. β1 integrin participates in B4GALT3 mediated cell migration and invasion β1 integrins are crucial cell-extracellular matrix (ECM) receptors that regulate numerous cell phenotypes including cell survival, migration, and invasion. In addition, glycosylation of β1 integrin has been found to modulate these biological functions (19) . We therefore investigated whether β1 integrin plays a role in B4GALT3-enhanced cell migration and invasion. Our results showed that knockdown of B4GALT3 significantly suppressed cell migration toward β1 integrin ligands, 
fibronectin and laminin, in SK-N-DZ and SK-N-BE ( Supplementary Fig. S6 ). Since SH-SY5Y and SK-N-AS cells could not migrate well toward ECMs under serum-free condition, 10% FBS was added to lower chamber as a chemoattractant. B4GALT3 overexpression significantly enhanced cell migration through fibronectin-or laminin-coated transwells in SH-SY5Y (Fig. 3A) and SK-N-AS cells ( Supplementary   Fig. S7A ). In addition, β1 integrin blocking antibody, but not control IgG, inhibited migration of vector transfected cells and blocked the B4GALT3-enhanced cell migration toward ECMs. By contrast, knockdown of B4GALT3 inhibited cell migration toward fibronectin or laminin in SK-N-DZ (Fig. 3B) and SK-N-BE cells (Supplementary Fig. S7B ). Furthermore, β1 integrin blocking antibody, but not control IgG, suppressed cell migration toward laminin in control siRNA knockdown SK-N-DZ (Fig. 3B) and SK-N-BE cells (Supplementary Fig. S7B ). These results indicate that β1 integrin plays a role in regulating B4GALT3-enhanced migration toward ECM proteins. Moreover, we also observed that B4GALT3-increased invasion was significantly suppressed by β1 integrin blocking antibody in SH-SY5Y (Fig. 3C) and SK-N-AS cells (Supplementary Fig. S7C ). In control siRNA-transfected SK-N-DZ (Fig. 3D) and SK-N-BE cells (Supplementary Fig. S7D ), β1 integrin blocking antibody could reduce cell invasion through matrigel. Together, these data suggest that β1 integrin plays a role in NB cell migration and invasion and is involved
in B4GALT3-enhanced migration and invasion in NB cells.
B4GALT3 modifies glycosylation and signaling of β1 integrin
Since β1 integrin is a crucial receptor for NB cell migration and invasion and B4GALT3-enhanced migration and invasion can be suppressed by β1 integrin blocking antibody, we therefore examined whether B4GALT3 could modify glycosylation and signaling of β1 integrin. Lectin pull down assay was performed to verify glycosylation changes of β1 integrin. Three lectins were used: RCA I, which binds preferentially to oligosaccharides with terminal galactose; DSL, which recognizes N-acetyllactosamine and oligomers containing repeated N-acetyllactosamine; and LEL, which binds to poly-N-acetyllactosamine.
Overexpression of B4GALT3 in SH-SY5Y cells increased binding of β1 integrin to RCAI and LEL lectins (Fig. 4A) . Furthermore, we found that the effect of B4GALT3
on LEL binding to β1 integrin could not be blocked by either O-glycan or N-glycan processing inhibitor ( Supplementary Fig. S8 ), suggesting that B4GALT3-modified poly-N-acetyllactosamines are present on both N-and O-glycans of β1 integrin. In SK-N-DZ cells, knockdown of B4GALT3 decreased binding of β1 integrin to RCA I (Fig. 4A ). These findings suggest that B4GALT3 can modify terminal galactose and poly-N-acetyllactosamine on β1 integrin in NB cells.
Research. We next analyzed whether β1 integrin-mediated signaling was modulated by B4GALT3. We found that phosphorylation of FAK was increased in SH-SY5Y/B4GALT3 cells on either fibronectin or laminin, but not on poly-L-lysine, compared with control transfectants (Fig. 4B) . In contrast, knockdown of B4GALT3 suppressed the phosphorylation of FAK in SK-N-DZ cells (Fig. 4B) . These results reveal that B4GALT3 can modify glycosylation of β1 integrin and regulate its downstream signaling pathways in NB cells.
B4GALT3 increases mature β1 integrin through delayed protein degradation
To investigate the effect of B4GALT3-altered glycosylation on β1 integrin, we examined the expression of β1 integrin in NB cells. Two different glycoforms of β1 integrin have been reported (20) . The mature form of fully glycosylated β1 integrin exhibits a molecular weight of about 130 kDa, while the immature form with partial glycosylation is around 115 kDa. Our data showed that overexpression or knockdown of B4GALT3 in NB cell lines had no significant influences on mRNA levels of β1 integrin ( Supplementary Fig. S9 ). Interestingly, we found that overexpression of B4GALT3 increased mature form, but not immature form, of β1 integrin in SH-SY5Y (Fig. 5A) and SK-N-AS ( Supplementary Fig. S10A Fig. S10B ). To further verify effects of B4GALT3 on the expression level of mature form of β1 integrin, flow cytometry was performed. Consistently, our data showed that the surface level of β1 integrin was increased in B4GALT3-transfected SH-SY5Y cells compared with vector-transfected cells, but was decreased in SK-N-DZ cells knocked down with B4GALT3 siRNA compared with control siRNA (Fig. 5B) .
5A) and SK-N-BE cells (Supplementary
To determine whether changes in the level of mature form of β1 integrin was due to altered protein stability, we performed protein degradation assays in cells treated with cycloheximide which blocks protein synthesis. After 9 h treatment of cycloheximide, mature form of β1 integrin decreased to 53 ± 8% and 84 ± 10% in vector-and B4GALT3-transfected SH-SY5Y cells, respectively (Fig. 5C ), suggesting that B4GALT3 overexpression delayed the degradation of mature form of β1 integrin.
Moreover, knockdown of B4GALT3 in SK-N-DZ cells decreased the mature form of β1 integrin to 75 ± 8% compared with 106 ± 7% for control siRNA knockdown (Fig.   5C ). Collectively, these results suggest that B4GALT3 stabilizes the mature form of β1 integrin to increase its surface expression on NB cells.
Discussion
GnT-V catalyzes the synthesis of β1,6GlcNAc branches on N-glycans that are It has been reported that protein levels of β1-integrin are decreased in more invasive NB cells (24) . Reduced β1-integrin is suggested to release cells from ECM attachment and increase cell migration and invasion. However, we found that in NB cells B4GALT3 overexpression elevates expression of the mature form of β1-integrin and enhances migration and invasion. Conversely, B4GALT3 knockdown in NB cells decreases mature β1-integrin levels and suppresses these phenotypes. Furthermore, β1-integrin blocking antibody significantly suppresses NB cell migration and invasion, which is consistent with our previous study indicating that β1-integrin blocking antibody suppresses SK-N-SH cell migration and invasion (18) . These results suggest that although low levels of β1-integrin are expressed on surfaces of invasive NB cells, activation of β1-integrin and enhancement of its downstream signaling are required for migration toward ECM and invasion through matrigel. Interestingly, several lines of evidence suggest that cell movement rates are maximal only at intermediate levels of adhesion (25) . Strong adhesion to the ECM blocks migration, whereas at low adhesion the traction force generated is not enough to increase movement (25) (26) (27) .
Research. Our results showed that B4GALT3-enhanced NB cell migration and invasion could be inhibited by β1-integrin blocking antibody. These findings suggest that the enhancement of β1-integrin activity to an optimal level is involved in the B4GALT3-facilitated migration and invasion of NB cells.
Glycosylation has been reported to regulate several properties of integrins, including protein conformation, receptor clustering, heterodimer formation, endocytosis, degradation rate, and recycling, as well as interactions between integrins and extracellular proteins (25) . All of which are able to control integrin functions and cellular properties. We found that B4GALT3 increases expression of lactosamine sugars on the mature form of β1-integrin, which delays β1-integrin degradation and thereby enhances its downstream signaling. Therefore, we suggest that B4GALT3 modulates β1-integrin functions at least, in part, via regulating protein turnover of mature β1-integrin on cell surfaces. In contrast, in human fibrosarcoma HT1080 cells, GnT-V enhances migration by modulating integrin clustering and subsequent signal transduction pathways without changes in surface levels of α5-or β1-integrin (16).
These findings suggest that the effects of B4GALT3 on β1-integrin are different from those generated by GnT-V, although both enzymes are able to increase poly-N-acetyllactosamine on β1-integrin. Since we found that B4GALT3 can generate poly-N-acetyllactosamine on both N-and O-glycans on β1-integrin, it is therefore reasonable to speculate that the differential effects mediated by B4GALT3 may result from the B4GALT3-modified poly-N-acetyllactosamine on O-glycans of β1-integrin.
In addition to protein degradation, it remains possible that altered glycosylation of β1-integrin mediated by B4GALT3 can activate β1-integrin directly via conformational changes, which lead to increased cell migration and invasion. Because β1-integrin is not the only acceptor substrate for B4GALT3, it will be very interesting to identify other acceptor substrates for a complete understanding of the mechanisms by which B4GALT3 regulates NB cell behaviors.
β1-integrins partner with α subunits to form 12 potential receptors, which bind to a wide range of RGD-containing ECM proteins, such as collagens, laminin, and fibronectin (28) . Bidirectional signals of β1-integrin play a crucial role in apoptosis, differentiation, survival, migration, invasion, tumor progression and metastasis (28) .
Interestingly, inhibition of β1-integrin or its downstream signaling partners has been shown to inhibit metastasis and to maintain tumor cells in a dormant state (28) .
Therefore, β1-integrin has been proposed to be a potential therapeutic target against cancer recurrence (28) . This study showed that B4GALT3 expression predicts unfavorable outcomes of NB patients. In addition, knockdown of B4GALT3
Research. IMD to modulate survival and invasiveness of neuroblastoma cells (31) . Since B4GALT3 can modulate protein levels and activity of β1-integrin as well as stromal tissues in tumor xenografts, further studies are required to establish the roles of B4GALT3 in alterations of tumor microenvironment.
Our results establish that B4GALT3 expression is a novel independent unfavorable prognostic factor for NB patients. The COG risk grouping is now widely accepted for prognostic discrimination and treatment allocation of NB patients (4) . NB patients in the low risk group have excellent outcomes, while NB patients in either the intermediate or the high risk group are two large groups showing prognostic heterogeneity. Additional prognostic factors may be required to further discriminate these two groups of patients. Here, we show that B4GALT3 expression predicts an unfavorable prognosis for NB patients in either intermediate or high risk group. Therefore, assessing B4GALT3 protein expression in NB tumors could provide complementary prognostic information in addition to COG risk grouping, allowing clinicians to determine the most appropriate therapy or to develop personalized treatment for the NB patients.
In summary, this study shows that B4GALT3 protein expression is an independent represented as mean ± SD from at least 3 independent experiments. **, P < 0.01. F, effects of B4GALT3 on NB cell invasion using matrigel invasion assays.
Chemoattractant in the lower chamber was 10% FBS. Data are shown as mean ± SD from at least 3 independent experiments. *, P < 0.05; **, P < 0.01. Signal intensity was presented as fold changes compared with control transfectants.
All results are presented as means ± SD from 3 independent experiments. *, P < 0.05; **, P < 0.01. 
